NCT03401346View on ClinicalTrials.gov

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

December 1, 2017

Study Completion Date

December 6, 2017

Conditions
Migraine Headache
Interventions
COMBINATION_PRODUCT

INP104

Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device

DRUG

Dihydroergotamine Mesylate (DHE)

Dihydroergotamine Mesylate (DHE) injection (intravenous)

COMBINATION_PRODUCT

Migranal Nasal Spray

Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump

Trial Locations (1)

3004

Centre for Clinical Studies/Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Impel Pharmaceuticals

INDUSTRY